Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Joel W. Hay & Zheng-Yi Zhou. (2011) Systematic literature review of economics analysis on treatment of mild-to-moderate bleeds with aPCC versus rFVIIa. Journal of Medical Economics 14:4, pages 516-525.
Read now
Read now
Isaac A. O. Odeyemi & Anne M. Danø. (2009) Optimising immune tolerance induction strategies in the management of haemophilia patients with inhibitors: a cost-minimisation analysis. Current Medical Research and Opinion 25:1, pages 239-250.
Read now
Read now
Jennifer M Stephens, Ashish V Joshi, Michael Sumner & Marc F Botteman. (2007) Health economic review of recombinant activated factor VII for treatment of bleeding episodes in hemophilia patients with inhibitors. Expert Opinion on Pharmacotherapy 8:8, pages 1127-1136.
Read now
Read now
Sandro B Rizoli & Talat Chughtai. (2006) The emerging role of recombinant activated Factor VII (rFVIIa) in the treatment of blunt traumatic haemorrhage. Expert Opinion on Biological Therapy 6:1, pages 73-81.
Read now
Read now
Ashish V. Joshi, Jennifer M. Stephens, Vicki Munro, Prasad Mathew & Marc F. Botteman. (2006) Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors. Current Medical Research and Opinion 22:1, pages 23-31.
Read now
Read now
IAO Odeyemi, PW Friederich & M Levi. (2004) Economic impact of recombinant activated factor VII in the control of bleeds associated with abdominal prostatectomy. Journal of Medical Economics 7:1-4, pages 107-115.
Read now
Read now
Articles from other publishers (20)
Katarina Steen Carlsson & Erik E. Berntorp. 2014. Textbook of Hemophilia. Textbook of Hemophilia
489
494
.
V. Jimenez-Yuste, R. Núñez, J. A. Romero, B. Montoro & B. Espinós. (2013) Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain. Haemophilia 19:6, pages 841-846.
Crossref
Crossref
J. W. HAY & Z. Y. ZHOU. (2011) Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors. Haemophilia, pages no-no.
Crossref
Crossref
J. O. O. OYESIKU. (2011) Home treatment of haemophilia patients with inhibitors. Haemophilia 17:2, pages 173-178.
Crossref
Crossref
Adam Gater, Thomas Thomson & Martin Strandberg-Larsen. (2017) Haemophilia B: impact on patients and economic burden of disease. Thrombosis and Haemostasis 106:09, pages 398-404.
Crossref
Crossref
E. BERNTORP. (2011) Importance of rapid bleeding control in haemophilia complicated by inhibitors. Haemophilia 17:1, pages 11-16.
Crossref
Crossref
Katarina Steen Carlsson & Erik Berntorp. 2010. Textbook of Hemophilia. Textbook of Hemophilia
409
414
.
M. A. ESCOBAR. (2010) Health economics in haemophilia: a review from the clinician’s perspective. Haemophilia 16, pages 29-34.
Crossref
Crossref
C. KNIGHT, A. M. DANØ & T. KENNEDY‐MARTIN. (2010)
A Rebuttal to the Commentary of J. W. Hay and Z.‐Y. Zhou.
Haemophilia
2009; DOI:10.1111/j.1365‐2516.2009.02117.x: “Commentary on Knight
et al.
: A systematic review of the cost‐effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors”
. Haemophilia 16:2, pages 369-371.
Crossref
Crossref
M. N. D. DI MINNO, G. DI MINNO, M. DI CAPUA, A. M. CERBONE & A. COPPOLA. (2009) Cost of care of haemophilia with inhibitors. Haemophilia 16:1.
Crossref
Crossref
C. KNIGHT, A. M. DANØ & T. KENNEDY-MARTIN. (2009) A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors. Haemophilia 15:2, pages 405-419.
Crossref
Crossref
C. W. YOU, S. Y. LEE & S. K. PARK. (2009) Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea. Haemophilia 15:1, pages 217-226.
Crossref
Crossref
WC LEE, A. V. JOSHI, S. WOOLFORD, M. SUMNER, M. BROWN, N. HADKER & C. L. PASHOS. (2008) Physicians’ preferences towards coagulation factor concentrates in the treatment of Haemophilia with inhibitors: a discrete choice experiment. Haemophilia 14:3, pages 454-465.
Crossref
Crossref
M. C OZELO, P. R VILLAÇA, J. O. S. C DE ALMEIDA, T. M. F BUENO, P. A. P DE MIRANDA, W. M HART & M KARAMALIS. (2007) A cost evaluation of treatment alternatives for mild-to-moderate bleeding episodes in patients with haemophilia and inhibitors in Brazil. Haemophilia 13:5, pages 462-469.
Crossref
Crossref
Katherine A Lyseng-Williamson & Greg L Plosker. (2007) Recombinant Factor VIIa (Eptacog Alfa). PharmacoEconomics 25:12, pages 1007-1029.
Crossref
Crossref
S. SEREMETIS, A. V. JOSHI & M. ASMUSSEN. (2006) Cost minimization model for treatment of minor bleeding episodes in inhibitor patients - methodological issues. Haemophilia 12:1, pages 108-109.
Crossref
Crossref
Albert Farrugia. (2006) Assessing Efficacy and Therapeutic Claims in Emerging Indications for Recombinant Factor VIIa: Regulatory Perspectives. Seminars in Hematology 43, pages S64-S69.
Crossref
Crossref
Cristina Negrini, F. Daniele, M. E. Mancuso, G. F. Rivolta & A. Tagliaferri. (2013) Implicazioni economiche del trattamento dei pazienti emofilici con inibitori: una revisione sistematica della letteraturaEconomic implications of treating patients with hemophilia and inhibitors: a systematic literature review. PharmacoEconomics Italian Research Articles 8:1, pages 33-44.
Crossref
Crossref
C. KNIGHT. (2005) Health economics of treating haemophilia A with inhibitors. Haemophilia 11:s1, pages 11-17.
Crossref
Crossref
K. G. Putnam, R. L. Bohn, B. M. Ewenstein, W. C. Winkelmayer & J. Avorn. (2005) A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors. Haemophilia 11:3, pages 261-269.
Crossref
Crossref